Shiga toxin 2 (Stx2A) is a potent bacterial toxin produced by certain strains of Escherichia coli, particularly enterohemorrhagic E. coli (EHEC). It plays a key role in disease progression by disrupting protein synthesis in host cells, leading to severe complications such as hemolytic uremic syndrome (HUS). Monoclonal antibodies targeting Stx2A offer a promising approach for neutralization, aiding in research and therapeutic applications. Their high specificity enhances detection and treatment strategies in microbiology and infectious disease studies.